1-4 of 4
Jane Engler
Close
Sort by
Journal Articles

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Devendra K Hiwase, Jane Engler, Verity Saunders, Deborah L. White, PhD, Timothy Hughes, MD, MBBS
Journal: Blood
Blood (2010) 116 (21): 1205.
https://doi.org/10.1182/blood.V116.21.1205.1205
Published: 2010
Journal Articles

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes
Journal: Blood
Blood (2007) 110 (12): 4064–4072.
https://doi.org/10.1182/blood-2007-06-093617
Published: 2007
Includes: Supplemental data
Journal Articles

OCT-1–mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Andrew C. W. Zannettino, Antony C. Cambareri, Steven R. Quinn, Paul W. Manley, Timothy P. Hughes
Journal: Blood
Blood (2006) 108 (2): 697–704.
https://doi.org/10.1182/blood-2005-11-4687
Published: 2006
Journal Articles

Low Baseline Intrinsic Sensitivity to Imatinib (High IC50) in CML Patients Is Due to Reduced Oct-1 Mediated Influx. Intrinsic Sensitivity to AMN107 Does Not Correlate with That of Imatinib and Uptake of AMN107 Is Not Oct-1 Mediated.

Deborah L. White, Verity A. Saunders, Jane Engler, Phuong Dang, Andrew C.W. Zannettino, Antony Cambareri, Steven Quinn, Paul Manley, Timothy P. Hughes
Journal: Blood
Blood (2005) 106 (11): 1081.
https://doi.org/10.1182/blood.V106.11.1081.1081
Published: 2005